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Abstract
Background
Genetic analysis of pathogenic organisms is a useful tool for linking human cases together
and/or to potential environmental sources. The resulting data can also provide information
on evolutionary patterns within a targeted species and phenotypic traits. However, the
instruments often used to generate genotyping data, such as single nucleotide polymor-
phisms (SNPs), can be expensive and sometimes require advanced technologies to imple-
ment. This places many genotyping tools out of reach for laboratories that do not specialize
in genetic studies and/or lack the requisite financial and technological resources. To address
this issue, we developed a low cost and low tech genotyping system, termed agarose-
MAMA, which combines traditional PCR and agarose gel electrophoresis to target phyloge-
netically informative SNPs.
Methodology/Principal findings
To demonstrate the utility of this approach for generating genotype data in a resource-con-
strained area (Madagascar), we designed an agarose-MAMA system targeting previously
characterized SNPs within Yersinia pestis, the causative agent of plague. We then used this
system to genetically type pathogenic strains of Y. pestis in a Malagasy laboratory not special-
ized in genetic studies, the Institut Pasteur de Madagascar (IPM). We conducted rigorous
assay performance validations to assess potential variation introduced by differing research
facilities, reagents, and personnel and found no difference in SNP genotyping results. These
agarose-MAMA PCR assays are currently employed as an investigative tool at IPM, providing
Malagasy researchers a means to improve the value of their plague epidemiological investiga-
tions by linking outbreaks to potential sources through genetic characterization of isolates and
to improve understanding of disease ecology that may contribute to a long-term control effort.
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Conclusions
The success of our study demonstrates that the SNP-based genotyping capacity of labora-
tories in developing countries can be expanded with manageable financial cost for resource
constraint laboratories. This is a practical formula that reduces resource-driven limitations to
genetic research and promises to advance global collective knowledge of infectious dis-
eases emanating from resource limited regions of the world.
Author summary
Although genetic characterization of pathogenic organisms is a powerful tool for investi-
gating outbreak origins and transmission, associated high upfront costs and demanding
technological maintenance exclude this tool for many under-resourced laboratories. Para-
doxically, resource constrained regions commonly suffer from high rates of infectious
diseases and could benefit most from genetic tracking tools. One such country is Mada-
gascar, which lacks resources to acquire high tech genetic typing equipment, yet suffers
from seasonal human plague outbreaks. A serious disease, plague is caused by the clonal
bacterium, Yersinia pestis, and is capable of causing human outbreaks. Using plague as a
model organism, we developed a genetic typing method that requires only basic, widely
used molecular machinery. Our tools target unique single mutations in the Y. pestis
genome to assign isolates to distinct phylogenetic groups with known geographical distri-
butions. Transfer of this technology to Madagascar permits genetic characterization of
strains from current outbreaks. This eliminates the need for external genetic analysis and
expands the research capacity of this resource-constrained laboratory by allowing rapid,
in-house strain typing. Ultimately, our goal is to help improve the ability of local institutes
to genetically characterize circulating strains, link outbreaks to originating sources, and
improve our understanding of the ecology of tropical diseases in resource-limited regions
of the world.
Introduction
Single nucleotide polymorphisms (SNPs) are highly valuable genetic markers that have
advanced our knowledge of diverse biological fields such as human health [1,2], infectious dis-
ease epidemiology [3–5], agriculture [6], and ecology [7], among others. In the study of infec-
tious diseases SNPs can be informative of bacterial phenotype, such as antibiotic susceptibility
[8,9], and also can be used to classify unknown strains. For non-recombining bacterial patho-
gens, most of their SNPs become fixed in the genome and are faithfully replicated throughout
future generations [3,10]. These stable signatures can be used to classify unknown strains into
known phylogenetic groups according to SNP profiles [3,11,12]. Within the context of epide-
miological investigations, these SNP profiles can link isolates from active outbreak sites to pos-
sible sources and help track disease transmission patterns [5,13,14].
Genotyping assays that use real-time PCR to identify single SNPs remain in demand despite
the wide-scale availability of whole genome sequence (WGS) data and continued reductions in
WGS costs. For many research facilities that are interested in small-scale studies or face
resource limitations, a WGS-based approach to SNP typing is not a feasible nor a desirable
option. A variety of other technological platforms have been employed for SNP typing and
SNP-genotyping tools for resource-limited areas
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have been extensively described in several publications [15–18]. Popular platforms for SNP
typing use real-time PCR instruments that employ Dual Probe TaqMan assays or melt-
MAMA SNP assays [19–21]. But real-time platforms are not commonly available in resource
constrained laboratories, due to their high upfront costs and the need for ongoing highly tech-
nical instrument maintenance. However, a more simplified method for SNP genotyping that
employs conventional PCR coupled with standard agarose gel electrophoresis (agarose-
MAMA) is a viable alternative in these settings. The advantage of this alternative method is
that it utilizes relatively inexpensive instruments that are almost universally available even in
developing nations where it is used for a variety of molecular applications. Much of this is due
to the simplicity of the agarose gel electrophoresis platform, in contrast to the complex instru-
mentation of the real-time platform [20,22].
To illustrate the effectiveness of agarose-MAMA as a SNP genotyping tool in resource con-
strained laboratories, we developed Y. pestis assays for use at the Institut Pasteur de Madagas-
car (IPM). Y. pestis is the bacterium infamously known as the causal agent of the disease
plague. Y. pestis is ecologically established on nearly every inhabited continent [12,23] and
remains a particularly significant threat to human health in developing nations in Africa and
especially the island country of Madagascar [24,25]. Primarily a zoonotic agent, Y. pestis has a
complex ecological cycle involving rodent-host populations and flea vectors. In unfortunate
circumstances, humans are incidental hosts [26]. Without prompt antibiotic treatment,
human death rates vary from 30–60% to 100% depending on the route of exposure, with pneu-
monic plague being the most deadly [24,25]. Within the last two decades, Madagascar has
reported some of the highest incidences of human plague infections throughout the world
[24]. Given that Y. pestis is a re-emerging public health threat in Madagascar [27–29] and
other developing African nations, performing SNP typing studies through the use of agarose-
MAMA tools could lead to greatly improved epidemiological investigations and to more effec-
tive disease management.
Here, we describe how we resolved technological limitations that prevented Y. pestis SNP
genotyping studies at IPM by: 1) re-designing a SNP-based Y. pestis genotyping system (from
melt-MAMA real-time platform to agarose-MAMA) to be compatible with existing resources
in Madagascar, and 2) validating these genetic tools at IPM for adoption. Collectively, these
achievements have removed a research barrier at IPM once imposed by technological dispari-
ties and serve as a promising model for building similar research capacities in other developing
nations affected by plague and/or other pathogens common to low-resource settings. In addi-
tion, these tools generate data that can be compared to other sequence-based methods and can
feed into existing global databases. This ability can strengthen scientific exchange between
affected countries and the international scientific community, thereby advancing the global
collective knowledge of dangerous infectious diseases.
Results and discussion
Removal of technological barriers: Agarose MAMA–a highly accurate
genetic typing tool
We present a SNP genotyping tool that uses standard genetic equipment and reagents that are
accessible to nearly any laboratory. The successful development of agarose-MAMA tools
removes the dependence on real-time instruments for conducting SNP-based epidemiological
studies. Due to emerging infectious diseases being most globally prevalent in resource chal-
lenged countries [30,31], building research capacities in these regions has been a goal for the
World Health Organization and other agencies charged with global biosafety, response, and
biosecurity efforts [32,33]. It is now possible for researchers in resource constrained locations
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to conduct SNP studies to obtain bacterial phenotype information such as antibiotic resistance
or phylogenetic information to more robustly understand the dynamics of disease transmis-
sion and potentially identify sources of human infections.
The phylogeny of Y. pestis in Madagascar has recently expanded [34] to include more phy-
logenetic groups (Fig 1) and the 18 assays developed for this study define a subset of these phy-
logenetic groups or lineages as illustrated on a simplified phylogeny (Fig 1). The genotyping
results generated from each agarose-MAMA was identical to independent SNP genotyping
technologies [34] when tested across the same diverse panel of 16 Y. pestis DNA strains. Assay
specificity remained intact when these agarose-MAMAs were tested on diverse types of nega-
tive controls (high levels of human, Leptospira spp., and Bacillus anthracis DNA, or a no tem-
plate water control). When the assays were employed in a stepwise, hierarchical order (Fig 2),
each isolate could be assigned to a single lineage or one subgroup as depicted in the simplified
Malagasy Y. pestis phylogeny (Fig 1). The equivalent performance of our agarose-MAMA tools
to melt-MAMAs [11] and other independent SNP technologies [34] demonstrate that MAMA
tools preserve their genotyping accuracy independent of the technology platform used.
Fig 1. Simplified SNP phylogeny of Y. pestis depicting subgroups identified in Madagascar. Colored
circles indicate phylogenetic groups as previously described [35][11,34]. Group names are assigned as letters
and sometimes followed by a number (e.g. s4). Black bars indicate the phylogenetic positions of the 18 SNPs
targeted for MAMA PCR design in this study.
https://doi.org/10.1371/journal.pntd.0006077.g001
SNP-genotyping tools for resource-limited areas
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Optimization of assays to obtain accurate genotypes
For the 18 selected SNPs, we were able to successfully design agarose-MAMAs to achieve
100% genotyping accuracy through a few key optimization steps. Only one of our assays failed
initial optimization efforts; however, when we redesigned the assay to target the reverse
complement of the reference template DNA (strain CO92), the assay was rescued to full func-
tionality. Essential validation steps included the identification of the optimal ratios for the con-
centration of the two forward primers (ancestral:derived) as described [20], ideal annealing
temperature for each assay, appropriate number of PCR cycles, and an occasional need for
MgCl2 concentration alteration in the reaction mix. These optimization strategies worked well
Fig 2. Flow chart providing the hierarchical organization of 18 SNP-genotyping assays. The hierarchy
provides the sequential order to allow for stepwise identification of the genotype of an unknown isolate.
Genetic subgroups are represented by colored circles labeled with each genetic subgroup. Individual assays
are represented by the black bar labeled with each assay ID. The derived and ancestral allele states for each
assay are indicated immediately above and below the black bar.
https://doi.org/10.1371/journal.pntd.0006077.g002
SNP-genotyping tools for resource-limited areas
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on 8 other bacterial pathogens [20] and should be applicable to many other pathogenic organ-
isms as well.
The GC-clamp (21–28 oligo base), added to derived MAMA forward primers but excluded
from ancestral MAMA forward primers, was sufficient to provide visible size differences
between the two allelic states when visualized on an agarose gel (Fig 3). A repeated pattern of
5’-cgggttcgggttcgggttcgggttcggg-3’did not appear to induce non-specific binding nor interact
with template DNA in an inhibitory manner. However, we observed that the GC-clamp on the
derived MAMA primer did frequently confer a competitive advantage over the ancestral
MAMA, as previously described for MAMA tools [20]. This competitive advantage resulted in
cross-hybridization of primers for a subset of assays. This phenomenon may be based on the
ability for GC rich DNA regions to anneal at lower temperatures compared to GC poor
regions. The GC-clamp of the derived MAMA primer likely anneals to its target amplicon at
lower temperatures compared to the no-clamp ancestral primer. As a consequence, the GC-
clamp primer anneals to the template at an earlier time point per PCR cycle than the no-clamp
primer, resulting in a competitive kinetic advantage. To correct for this competitive advantage,
we followed published guidelines [20] by increasing the ancestral primer concentration relative
to the derived primer concentration of the affected assays. In these skewed reaction mixes, the
ancestral primer had>1x-4x concentration compared to its paired derived primer. We have
detected best results with 4:1 and 2:1 (ancestral:derived) primer ratios, depending on the assay.
We obtained maximal assay specificity by a combination of customizing the annealing tem-
perature per assay and/or adjusting the MgCl2 concentrations. Most of our assays accurately
genotyped SNP alleles at annealing temperatures around 60˚C; however, some assays had
non-specific product at this condition. For these assays, non-specific PCR products were pres-
ent in our negative controls and/or in our sample PCR product, visualized as extra banding on
Fig 3. Size differences in allele-specific PCR products. A) Schematic of PCR amplicons originating from
ancestral and derived genomic templates. For both PCR amplicons, gray represents sequence originating
from the primers (forward and reverse) and synthesized internal sequence from PCR extension. The primer
sequence and synthesized internal sequence within the amplicon are indicated by the bracket. For the derived
amplicon, the blue represents the incorporated GC-clamp which originates from the 5’end of the derived
MAMA forward primer. The SNP region for each amplicon is represented in green (ancestral) and yellow
(derived) and the deliberate antepenultimate mutation is represented as red (ancestral) and light blue
(derived). B) Allele-specific PCR products migrate at different rates on a 2% agarose gel due to their size
difference as conferred by the GC-clamp.
https://doi.org/10.1371/journal.pntd.0006077.g003
SNP-genotyping tools for resource-limited areas
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a gel. A reduction of MgCl2 concentration by 0.5 mM was sufficient to greatly increase the
specificity of most assays, as evidenced by the elimination of non-specific amplification. But
this reduction in MgCl2 decreased the PCR robustness in a subset of assays. To address this
loss, the annealing temperatures were reduced in affected assays while still preserving SNP
specificity. For the few assays that did not respond to lowered MgCl2 strategy, the raising of
annealing temperatures while still maintaining the normal 2.0 mM concentration of MgCl2
yielded improvements in reducing non-specific products.
Assay function on clinical samples
The assays described here are capable of genotyping directly from complex clinical samples if
pathogen DNA levels are sufficient (Fig 4). This capability is highly important as nearly
43.32% of 775 F1 RDT [36] positive human plague cases between 2011–2015 in Madagascar
and many environmental samples (rodents and fleas) do not yield live isolate culture (IPM rec-
ords). Using two agarose MAMA tools (Mad-05 and Mad-43) to demonstrate proof of princi-
pal, we were able to determine that the three complex clinical samples belonged to group I
lineage and not group II. This genetic assignment for these samples matched the results of a
recent publication [34]. These samples were not further tested on additional agarose-MAMAs.
Out of five complex clinical samples positive for the high copy plasmid pla gene [37] only four
were positive for Y. pestis chromosomal DNA, assessed by a TaqMan assay targeting the 3a
Fig 4. Agarose-MAMA is capable of genotyping Y. pestis directly from complex clinical samples if
pathogen targets are at sufficient levels. (A) Agarose-MAMA (Mad-43) gel showing the PCR products for
two template controls at the expected size for each respective ancestral and derived allele state (#1 and #2,
respectively). Three complex clinical samples (#3-#5) also yielded PCR products with the size expected of an
ancestral genotype. Two other complex clinical samples (#6 & #7) showed no PCR products but displayed a
banding pattern consistent with NTC negative controls. (B) To assess the relative quantity of the Y. pestis
target in the five clinical samples (#3, #4, #5, #6, #7), we generated amplification plots of these clinical
samples on a TaqMan 3a assay used to target Y. pestis chromosomal DNA. Three clinical samples (#3-#5)
showed amplified at a mid-range cycle-time (Ct) value consistent with high copy numbers of template DNA
[21]. These same samples showed a robust signal of a PCR product on the MAMA gel. The two samples (#6
& #7) that failed on the MAMA gel showed a high Ct value and failed amplification, respectively, when tested
by real-time PCR. The pairing of TaqMan 3a assay with MAMA gel results on the same templates provided
insight to the genotyping capability of MAMA tools on complex clinical samples with low-level target template.
https://doi.org/10.1371/journal.pntd.0006077.g004
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gene (Fig 4 and S3 Appendix). Of the four 3a-positive samples, one isolate (Yp3182) gave a late
amplification with the 3a assay resulting in a Ct value of 36 using real-time PCR. This indicates
a very low concentration amount for this clinical extract, near a single copy of pathogen DNA
[20,21]. The other three samples (Yp2483, Yp2486, Yp2485) (Fig 4) generated Ct values rang-
ing from 24–27, which indicates higher concentrations of Y. pestis chromosomal DNA in these
clinical samples. These more concentrated Y. pestis clinical samples were successfully geno-
typed by agarose-MAMA tools following an increase in the number of PCR cycles. The low-
level sample (Yp3182) failed to amplify PCR product using agarose-MAMA tools. Together,
these results indicate that agarose-MAMAs can genotype directly from complex clinical sam-
ples if the pathogen target (Y. pestis DNA) is of sufficient concentration. Published studies
show that TaqMan assays are highly sensitive [20,21] and can readily detect minute amount of
template not detectable using melt-MAMAs [20]. Our results suggest that the same is true for
agarose-MAMAs (Fig 4).
Transfer of technology–the minor effects of different research facilities
and reagents
Following the transfer of our agarose-MAMA tools to the IPM facility, a subset of our agarose-
MAMAs was validated for genotyping accuracy. The differing instruments and reagents used
at IPM introduced very little variability on assay performance when tested on the same DNA
panel previously used at NAU (Fig 5). The optimized PCR conditions identified at NAU for
the assays were suitable for most of the assays when conducted at IPM.
Fig 5. Mad-05 MAMA tool showed congruent genotyping results when generated across two research
institutes using identical DNA samples. Side by side comparison of Agarose-MAMA gel images generated
at NAU (top) and IPM (bottom) using different reagents and instruments. Y. pestis sample names follow the
designation scheme practiced at IPM. Individual samples are designated an ID # according to consecutive
order of collection per a given year. Strain 87/11 was the 87th isolate collected in 2011.
https://doi.org/10.1371/journal.pntd.0006077.g005
SNP-genotyping tools for resource-limited areas
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The most apparent difference in assay performance between the two laboratories was an
increase in non-specific amplification at high fragment size (Fig 5) and, for some assays, also
in our negative controls at IPM, which was not observed at NAU. These non-specific frag-
ments did not affect the MAMA’s capability to accurately genotype isolates. Band profiles were
not distinctly in line with either the ancestral or derived product but rather appeared either
as a smear across both profiles or as a much fainter band falling between the ancestral and
derived fragment sizes. We suspect that the basis of this performance difference is due to dif-
ferent Taq polymerases used between the two institutions. NAU employed an antibody-immo-
bilized Taq polymerase (Invitrogen, Carlsbad, CA), which has been characterized as having no
polymerase activity prior to a hot-start step in the thermal cycle protocol [38]. However, IPM
utilizes regular Taq polymerase, which may begin product synthesis with primers and template
in the master mix prior to PCR thermal cycling [38]. Although master mix preparation was
done on ice to suppress premature Taq polymerase activity, additional bands above the target
PCR product and faint bands in the NTC amplification suggest that pre-PCR Taq activity was
not completely suppressed (Fig 5). We therefore reduced the concentration of MgCl2 in five of
our assays (Mad-43, Mad-46, Mad-12, Mad-36 and Mad-58) to 1.5mM and observed the elimi-
nation of amplification in the negative controls in most of the affected assays. Reduction of
MgCl2 also imparted a general improvement of assay specificity for positive control and test
isolates. Surprisingly, the reduction of MgCl2 did not necessitate a corresponding increase in
the number of PCR cycles for most assays, contrary to the results observed in our laboratory at
NAU. Once again, this may be a result of differences in Taq polymerase activity between the
two institutions although we have not found any published evidence of this occurring else-
where. As a way to rule out possible contamination as a source of non-specific banding, all sur-
faces used for the preparation of PCR reaction mixtures were sterilized with UV light for 15
minutes and decontaminated with 70% ethanol. Following slight modifications, we found that
results of the majority of our assays at IPM aligned very well with results produced at NAU
(Fig 5 and S5 Appendix).
Advancing global collective knowledge by building research capacity
Our success in developing agarose-MAMA tools and transferring them to IPM facility in
Madagascar demonstrates that this SNP genotyping strategy can be achieved with existing
technologies routinely used in developing nations (Fig 5). The transferred agarose-MAMA
technology is now in regular use at IPM and was recently used to infer the source of a 2015
pneumonic outbreak [39]. There is ample evidence that this same assay design strategy would
transfer well to many other pathogenic organisms [20]. This would allow institutions in devel-
oping countries to perform molecular studies in-house and on local infectious organisms. The
current methods largely used for short-term control efforts are presence/absence assays (PCR
based [40] or protein based [36]) that diagnose the causative agents of disease outbreaks but
provide no genetic resolution. Having in-house capabilities to genetically discriminate goes
beyond what presence/absence assays can provide, therefore, resource-constrained laborato-
ries will be able to advance their epidemiological capabilities over the status quo. The SNP data
they generate locally can be shared among research institutes and compared to existing global
databases. These advanced capabilities would accelerate the understanding of plague ecology,
persistence, and evolution; which in turn could beneficially inform strategies for disease
control.
Building research capacity in low-resource settings is an important endeavor for global bio-
safety, response, and biosecurity preparedness [32,33]. Our study is a successful model of
achieving this goal pragmatically. We successfully developed and transferred genetic tools to a
SNP-genotyping tools for resource-limited areas
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developing nation. The design principles for this technology, which we detail above, can be
applied to diverse pathogen species [20]. The use of MAMA technology will give the scientific
community the means to gain insight into the genetic patterns and population structure of
many neglected diseases. This is a practical formula that will advance global collective knowl-
edge of infectious diseases emanating from more impoverished regions of the world.
Materials and methods
Ethics statement
The 16 archival strains and five clinical samples were not subject to IRB regulations because
they did not meet the federal definition of human subjects research according to 45 CFR
46.102 (f). All samples underwent de-identification of patient information prior to Northern
Arizona University (NAU) transfer. They were collected as part of the medical workup man-
dated by the Ministry of Health in Madagascar and not for the purpose of this study. For this
reason the strains used in this study does not meet the federal definition of human subjects
research according to 45 CFR 46.102 (f)and therefore are not subject to review from NAU
Institutional Review Board.
DNA
DNA samples utilized in this study were obtained from 16 Y. pestis isolates and 5 clinical sam-
ples (bubo aspirates and sputum) collected from suspected human plague cases (Table 1). The
16 archival strains and 5 clinical samples (Table 1) originated from diverse geographic loca-
tions in Madagascar and were collected as described in a recently published study [34]. Our
assays worked well on DNA concentrations that ranged from 1 ng to100 pg. Molecular confir-
mation of Y. pestis in five clinical samples was based on PCR detection of the pla gene located
in a high copy number plasmid PCP1 in addition to positive F1 RDT [28,36,37,41,42].
SNP groups
Eighteen previously published SNPs [11,34,35] specific, or canonical [3], for a subset of distinct
phylogenetic groups within the Y. pestis Malagasy phylogeny (Fig 1) were selected as the targets
of agarose MAMA genotyping assays following published guidelines [20]. These selected SNPs
can be used in a hierarchical way (Fig 2; Table 2) to assign an unknown strain to one of the
most common lineages or phylogenetic subgroups in Madagascar [11,34,35,43].
Assay design
The common reverse primer and two forward allele-specific MAMA primers for each assay
were designed using NetPrimer analysis software (Premier Biosoft, Palo Alto, CA). One for-
ward primer represents the original SNP allele, referred to as “ancestral” and the other repre-
sents the mutated SNP allele, referred to as “derived”. The MAMA primers for each assay were
designed to compete for the same SNP locus on the template and the resulting amplicon prod-
uct is generated by the allele-specific MAMA primer that most closely matches the template.
To differentiate between the amplicon products of the derived and ancestral genotypes,
additional length was added on the derived amplicon product but not the ancestral product.
This was achieved by adding 21–28 oligonucleotides rich in GC content at the 5’end of the
derived MAMA forward primer (GC-clamp) (Fig 3). Since the primers are incorporated in the
final amplicon product, the addition of the GC-clamp on the derived MAMA forward primer
resulted in derived amplicon products that were 21–28 bp longer than their ancestral amplicon
counterparts.
SNP-genotyping tools for resource-limited areas
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To maximize the visible size differences between the two allelic-specific amplicons when
viewed on an agarose gel, the size of the PCR amplicon was restricted to 80 bases total
length. Amplicons within ~80 bases show the greatest migration difference on a gel when
small size differences exist. This is the case with our derived and ancestral allele-specific PCR
products, which differ between 21–28 bases (Fig 3, Table 3, S2 Appendix). Additionally,
through the use of the GC-clamp, our assays retained the capability of SNP genotype discrimi-
nation on a real-time PCR platform, which is based on differential melt-curve properties of
each SNP-specific PCR product [20].
PCR conditions and size based genotype discrimination
Initial PCR conditions were identified at NAU. PCR conditions for different assays varied and
are described in Table 3. PCR amplification per assay was carried out in 20 μL volume with the
following reagents (see S1 Appendix for volume of each reagent): for one reaction, 1x PCR buffer
without MgCl2, MgCl2 range of 1.5–2.5 mM, 0.30 mM deoxynucleoside triphosphate, 1.6 units
of platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA), both sets of forward MAMA
primers (derived and ancestral allele-specific) with one common reverse primer at 0.40 μL each
(for a 1:1 ratio), molecular grade water to achieve 18 μL total volume and 2.0 μL of diluted DNA
template at ~1ng/μL per reaction. We did not directly test our assays on genomic DNA concen-
trations below 100 pg but previously published work suggests that the MAMA approach is sensi-
tive to DNA amounts below 100 pg [20]. For each set of reactions, at least one of each ancestral
and derived allele templates were used as positive controls as well as at least two no-template
controls (NTC). Thermal cycling parameters for the eighteen assays are as follows: initial dena-
turation at 94˚C for 5 min followed by 30–40 cycles of 94˚C for 30 s, 51˚C -67.3˚C (Table 3) for
30 s, and 72˚C for 30 s, with a final extension at 72˚C for 5 min. All PCR amplifications were per-
formed with a MJ Research PTC 200 thermal cycler (BioRad, Hercules, CA).
Conditions of agarose gel electrophoresis for PCR amplicons included adding 4 μL of 6x
loading dye 0.25 w/v xylene cyanol FF and 30% v/v glycerol, water (Thermo Fisher scientific,
Waltham, MA) to individual PCR products to achieve a 1x final dye concentration. Individual
reactions (20 μL) mixed with loading dye were loaded onto a 2% agarose gel matrix; 100 bp
DNA ladder (Invitrogen, Carlsbad, CA) was used for size referencing. Gels were prepared in
1x lithium borate buffer (S2 Appendix) and stained with SybrSafe dye (Life Technologies,
Carlsbad, CA). Electrophoresis was conducted at 300V for 25–30 minutes and viewed under
UV transillumination.
The genotyping accuracy of our SNP assays was validated using positive DNA controls that
represented known ancestral and derived allele states for each SNP target. Assay accuracy was
further assessed by testing them on 16 genomic DNA extracts of Malagasy Y. pestis strains
belonging to known diverse phylogenetic groups (Table 1) based on amplicon sequencing
[34]. To assess assay capability to genotype Y. pestis directly from complex DNA samples (con-
taining high levels of host DNA), we tested the performance of each assay on a positive control
sample comprised of high concentrations of human DNA with our positive control Y. pestis
DNA extract (strain A1122). To further assess this capability, we tested two assays (Mad-05
and Mad-43) on five human complex samples confirmed to be plague positive. This confirma-
tion was based on Y. pestis-specific TaqMan assay targeting a high copy plasmid pla gene [37].
We assessed the limit of detection of our MAMA tools on these five human clinical samples by
testing them on a new TaqMan assay designed for the chromosomal 3a gene (Fig 4 and S3
Appendix).
To confirm the specificity of the assays to the Y. pestis genome we tested assay performance
on DNA extracts of Bacillus anthracis, human DNA background, and no template water
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control. To compare assay performance at different research facilities, NAU and IPM jointly
conducted a second validation study on the IPM laboratory premises using IPM PCR reagents
and instrument (Fig 5). Thirteen of the eighteen assays were selected for validation (Table 3).
At IPM, specificity was confirmed by testing on Leptospira interrogans serovar Canicola and
no template controls. PCR was prepared for each assay using the Taq Core Kits 10, Cat#
EPTQK300 PCR reagents (MP Biomedicals, Santa Ana, CA) and amplification was conducted
using AB Applied Biosystems Veriti 96 Well Thermal Cycler thermal cycle (ThermoFisher Sci-
entific, Waltham, MA). Electrophoresis was performed using 2% agarose gels visualized on a
Gelscan (Bio-Rad, Hercules, CA).
Supporting information
S1 Appendix. PCR master mix calculation sheet indicating final concentration and volume
addition of each reagent.
(DOCX)
S2 Appendix. Side by side comparison of 2% agarose gel electrophoresis in a 1x Lithium
Borate and 1x TAE matrix. Electrophoresis was conducted with identical PCR products,
equipment and agarose gel conditions. The two runs differ only in buffer solution used.
(DOCX)
S3 Appendix. Y. pestis 3a TaqMan assay design.
(DOCX)
S4 Appendix. SNP allele state for the 16 isolates shown in Table 1.
(DOCX)
S5 Appendix. Agarose gel pictures for each assays generated at both NAU and IPM or
NAU only.
(DOCX)
S6 Appendix. Agarose gel pictures of negative controls (human background DNA and
Bacillus anthracis–A0635 and A0643) on a subset of MAMA tools.
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